Thomas John Dietz Purchases 50,000 Shares of Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Stock

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGRGet Rating) Director Thomas John Dietz acquired 50,000 shares of Eiger BioPharmaceuticals stock in a transaction on Monday, January 23rd. The shares were bought at an average cost of $1.43 per share, with a total value of $71,500.00. Following the completion of the transaction, the director now owns 50,000 shares of the company’s stock, valued at $71,500. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink.

Thomas John Dietz also recently made the following trade(s):

  • On Thursday, December 22nd, Thomas John Dietz sold 22,500 shares of Eiger BioPharmaceuticals stock. The shares were sold at an average price of $1.17, for a total transaction of $26,325.00.

Eiger BioPharmaceuticals Price Performance

EIGR traded down $0.05 on Wednesday, hitting $1.37. 292,723 shares of the stock were exchanged, compared to its average volume of 590,720. The company has a debt-to-equity ratio of 0.50, a current ratio of 5.45 and a quick ratio of 5.34. Eiger BioPharmaceuticals, Inc. has a 12 month low of $0.96 and a 12 month high of $10.02. The firm has a market capitalization of $60.38 million, a price-to-earnings ratio of -0.57 and a beta of 1.64. The business has a 50-day moving average of $2.14 and a two-hundred day moving average of $5.44.

Eiger BioPharmaceuticals (NASDAQ:EIGRGet Rating) last posted its quarterly earnings results on Thursday, November 3rd. The biotechnology company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.07). The firm had revenue of $4.02 million for the quarter, compared to analyst estimates of $3.93 million. Eiger BioPharmaceuticals had a negative return on equity of 106.48% and a negative net margin of 660.21%. Sell-side analysts forecast that Eiger BioPharmaceuticals, Inc. will post -2.28 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

EIGR has been the subject of several research reports. Citigroup dropped their price target on Eiger BioPharmaceuticals from $23.00 to $4.00 in a report on Friday, December 9th. StockNews.com cut shares of Eiger BioPharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, November 4th. BTIG Research lowered their price target on shares of Eiger BioPharmaceuticals from $48.00 to $9.00 in a research report on Monday, December 12th. Finally, Robert W. Baird cut their price objective on shares of Eiger BioPharmaceuticals from $29.00 to $3.00 in a report on Friday, December 9th.

Hedge Funds Weigh In On Eiger BioPharmaceuticals

A number of institutional investors have recently modified their holdings of the business. Sigma Planning Corp raised its stake in Eiger BioPharmaceuticals by 2.2% during the second quarter. Sigma Planning Corp now owns 63,700 shares of the biotechnology company’s stock worth $401,000 after acquiring an additional 1,400 shares in the last quarter. Legal & General Group Plc lifted its stake in Eiger BioPharmaceuticals by 62.0% in the 2nd quarter. Legal & General Group Plc now owns 4,327 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 1,656 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in Eiger BioPharmaceuticals by 2.3% in the first quarter. Charles Schwab Investment Management Inc. now owns 88,711 shares of the biotechnology company’s stock valued at $737,000 after buying an additional 1,953 shares in the last quarter. Nuveen Asset Management LLC grew its stake in shares of Eiger BioPharmaceuticals by 2.3% during the third quarter. Nuveen Asset Management LLC now owns 102,103 shares of the biotechnology company’s stock worth $768,000 after buying an additional 2,309 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its holdings in shares of Eiger BioPharmaceuticals by 2.3% during the 2nd quarter. JPMorgan Chase & Co. now owns 114,658 shares of the biotechnology company’s stock valued at $722,000 after acquiring an additional 2,537 shares in the last quarter. Institutional investors and hedge funds own 69.08% of the company’s stock.

Eiger BioPharmaceuticals Company Profile

(Get Rating)

Eiger BioPharmaceuticals, Inc engages in the development and commercialization of foundational therapies for Hepatitis Delta Virus. It is also developing avexitide as a treatment for Post-Bariatric Hypoglycemia. The company was founded by David A. Cory and Glenn S. Jeffrey on November 6, 2008 and is headquartered in Palo Alto, CA.

Featured Stories

Receive News & Ratings for Eiger BioPharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger BioPharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.